What question did this study set out to answer?

This research aims to assess a novel cell-based nanoplatform for treating pulmonary arterial hypertension (PAH).

February 26, 2026Open Access

Neutrophil-mediated delivery of curcumin-loaded manganese-doped zeolitic imidazolate framework-8 nanozymes for pulmonary arterial hypertension

Key Points

This research aims to assess a novel cell-based nanoplatform for treating pulmonary arterial hypertension (PAH).
Developed a neutrophil-mediated delivery system for curcumin-loaded manganese-doped nanostructures.
Evaluated antioxidant and anti-inflammatory effects in a cellular model of PAH.
Assessed the impact on EndoMT inhibition to regulate vascular remodeling.
Demonstrated significant alleviation of PAH symptoms in the tested model.
Observed strong antioxidant and anti-inflammatory effects of the nanoplatform.
Inhibition of EndoMT was confirmed, indicating a mechanism to prevent vascular remodeling.

Abstract

NEMZC represents a safe, targeted, and multifunctional cell‑based nanoplatform that effectively alleviates PAH through dual antioxidant/anti‑inflammatory action and EndoMT inhibition, demonstrating strong potential for clinical translation.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper